Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported its fourth quarter and full-year financial results for 2020, highlighting pivotal advancements in its oncology pipeline and strategic collaborations. As of December 31, 2020, the company had cash and marketable securities of approximately $338.5 million, enabling operations into 2023. Significant increases in research and development expenses reached $29.5 million in Q4 2020. The net loss for Q4 2020 was $40.4 million, compared to $14.5 million in the previous year.
Key developments included the initiation of multiple early-stage clinical trials and a collaboration with Tempus to enhance research capabilities.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced three accepted abstracts for the AACR Annual Meeting 2021, including a late-breaking presentation on its WEE1 inhibitor, ZN-c3. The meeting will occur virtually from April 10-15 and May 17-21, 2021. Highlights include:
- A late-breaker session on the clinical activity of ZN-c3 in advanced solid tumors.
- Poster presentations on ZN-c3's selectivity and ZN-e4's anti-tumor effects in EGFR mutant lung cancer.
Data supports Zentalis' ability to differentiate its oncology therapeutic candidates.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced a strategic collaboration with Tempus to enhance its research capabilities. This partnership will utilize Tempus' patient-derived organoid biological modeling platform, mainly to evaluate Zentalis' WEE1 inhibitor, ZN-c3, for its effectiveness in various cancer treatments. ZN-c3 aims to induce DNA damage in cancer cells to inhibit tumor growth. The collaboration will help identify patient populations most likely to benefit from ZN-c3, positioning Zentalis favorably for clinical advancements.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced initial clinical data from its Phase 1 monotherapy trial of ZN-c3, a WEE1 inhibitor targeting advanced solid tumors. The data will be presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, scheduled for April 10-15 and May 17-21. ZN-c3 aims to induce DNA damage in cancer cells, promoting cell death and tumor regression. Currently, Zentalis is also conducting a Phase 1b trial combining ZN-c3 with chemotherapy and plans to initiate a Phase 2 trial for uterine serous carcinoma by year-end.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) appointed Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki brings over a decade of experience in life sciences investment banking and business development. As a previous CFO of VelosBio, which was acquired by Merck, he has significant expertise in finance and strategic advising. His leadership is expected to enhance Zentalis' corporate financial strategy as the company advances its pipeline of oncology therapeutics, including ZN-c5 and ZN-c3.
On February 5, 2021, Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in two virtual investor conferences by CEO Anthony Sun, MD. The first event is the Guggenheim Healthcare Talks 2021 Oncology Days on February 12 at 1:30 p.m. EST, and the second is the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 10:00 a.m. EST. Live webcasts can be accessed from Zentalis' website, with archived versions available after the events. Zentalis focuses on developing small molecule therapeutics targeting cancer pathways.
Zentalis Pharmaceuticals has initiated patient dosing in three clinical trials for its oral SERD, WEE1 inhibitor, and BCL-2 inhibitor product candidates. These include a Phase 1b trial with ZN-c5 and abemaciclib for ER+/HER2- advanced breast cancer, a Phase 1 trial with ZN-c3 in advanced ovarian cancer, and a Phase 1 trial with ZN-d5 for acute myeloid leukemia and Non-Hodgkin’s Lymphoma. The trials aim to assess safety, tolerability, and pharmacokinetics, with potential implications for future treatment protocols in oncology.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in two virtual investor conferences featuring CEO Anthony Sun. The first event is the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 5:00 p.m. GMT, where Sun will engage in a fireside chat. The second is the SVB Leerink Oncology 1x1 Day, also on November 19, 2020, focusing on one-on-one meetings. A live webcast of the fireside chat will be accessible on the company's website, alongside an archived version post-event.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced topline results from its Phase 1 trial of ZN-c5 in ER+/HER2- advanced breast cancer, reporting a clinical benefit rate of 40%. A Phase 2 trial is set to begin in H1 2021. The company has also raised approximately $166 million from its recent stock offering. Financial results show a net loss of $34.7 million for Q3 2020, up from $12.6 million in Q3 2019, with R&D expenses significantly increasing to $24.7 million, attributed to advancing multiple clinical trials amid ongoing COVID-19 disruptions.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a Key Opinion Leader (KOL) virtual meeting on September 24, 2020, focused on its WEE1 inhibitor, ZN-c3, for treating advanced solid tumors. Presenters include Dr. Kwok-Kin Wong and Dr. Gordon Mills, who will discuss the ongoing clinical strategy and the potential of ZN-c3 in cancer treatment. ZN-c3 aims to induce DNA damage in cancer cells to promote cell death and prevent tumor growth. A Phase 1/2 trial is underway, with plans for a Phase 1b trial combining ZN-c3 with chemotherapy in advanced ovarian cancer.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
